Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
The introduction of 'compact' accelerator mass spectrometers into biomedical science, including use in drug metabolism and bioanalytical applications, is an exciting recent development. Comparisons are presented here between a more established and relatively large tandem accelerator which operates at up to 5 MV and a conventional laboratory-sized 250 kV single-stage accelerator mass spectrometer. Biological samples were enriched with low levels of radiocarbon, then converted into graphite prior to analysis on each of the two instruments. The data obtained showed the single-stage instrument to be capable of delivering comparable results, and thus able to provide similar study support, with that provided by the 5 MV instrument, without the significant overheads and complexities which are inherent to the operation of the larger instrument. We believe that the advent of these laboratory-sized accelerator mass spectrometry (AMS) instruments represents a real turning point in the potential for application of AMS by a wider user group.
Young
G C
GC
DMPK, GlaxoSmithKline, Ware SG12 0DP, UK. graeme.c.young@gsk.com
Corless
S
S
Felgate
C C
CC
Colthup
P V
PV
D002250:Carbon Radioisotopes / Q000032:analysis; D006108:Graphite / Q000032:analysis / Q000737:chemistry; D006801:Humans; D013058:Mass Spectrometry / Q000295:instrumentation / Q000379:methods*; D010315:Particle Accelerators; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D013395:Sucrose / Q000737:chemistry; D053719:Tandem Mass Spectrometry / Q000295:instrumentation / Q000379:methods*
D002250:Carbon Radioisotopes; D004364:Pharmaceutical Preparations; D013395:Sucrose; D006108:Graphite